Table 1. Patients’ characteristics.
| Variable | All patients (n=824) | Pure UC (n=792) | UC with variant (n=32) | P value |
|---|---|---|---|---|
| Age, year, median [range] | 74 [32–94] | 74 [32–94] | 78 [51–88] | 0.011 |
| Follow-up, month, median [range] | 28 [1–135] | 28 [1–135] | 16 [1–54] | 0.0002 |
| Sex, n (%) | ||||
| Male | 588 (71.4) | 567 (71.6) | 21 (65.6) | 0.47 |
| Female | 236 (28.6) | 225 (28.4) | 11 (34.4) | |
| Charlson comorbidity index, n (%) | ||||
| 0 | 638 (77.4) | 617 (77.9) | 21 (65.6) | 0.25 |
| 1 | 150 (18.2) | 140 (17.7) | 10 (31.3) | |
| ≥2 | 36 (4.4) | 35 (4.4) | 1 (3.1) | |
| Laterality, n (%) | ||||
| Right | 395 (47.9) | 379 (47.9) | 16 (50.0) | 0.81 |
| Left | 429 (52.1) | 413 (52.1) | 16 (50.0) | |
| Hydronephrosis, n (%) | ||||
| Absent | 397 (48.2) | 384 (48.5) | 13 (40.6) | 0.38 |
| Present | 427 (51.8) | 408 (51.5) | 19 (59.4) | |
| Operative method, n (%) | ||||
| Open | 236 (26.6) | 226 (28.5) | 10 (31.3) | 0.38 |
| Laparoscopic | 588 (71.4) | 566 (71.5) | 22 (68.7) | |
| Tumor location, n (%) | ||||
| Renal pelvis | 399 (48.4) | 385 (48.6) | 14 (43.8) | 0.22 |
| Ureter | 374 (45.4) | 356 (44.9) | 18 (56.2) | |
| Both | 51 (6.2) | 51 (6.4) | 0 | |
| Tumor grade, n (%) | ||||
| Low grade | 157 (19.0) | 155 (19.6) | 2 (6.3) | 0.06 |
| High grade | 595 (72.2) | 566 (71.5) | 29 (90.6) | |
| NR | 72 (8.7) | 71 (9.0) | 1 (3.1) | |
| Pathological T stage, n (%) | ||||
| pTa/is/1 | 372 (45.1) | 367 (46.3) | 5 (15.6) | <0.001 |
| pT2 | 104 (12.6) | 103 (13.0) | 1 (3.1) | |
| pT3 | 308 (37.4) | 284 (35.9) | 24 (75.0) | |
| pT4 | 40 (4.8) | 38 (4.8) | 2 (6.3) | |
| Lymph node status, n (%) | ||||
| pN0 | 227 (27.5) | 219 (27.7) | 8 (25.0) | 0.73 |
| pN1–2 | 62 (7.5) | 58 (7.3) | 4 (12.5) | |
| pNx | 535 (64.9) | 515 (65.0) | 20 (62.5) | |
| Concomitant CIS, n (%) | ||||
| Absent | 696 (84.5) | 669 (84.5) | 27 (84.4) | >0.99 |
| Present | 128 (15.5) | 123 (15.5) | 5 (15.6) | |
| LVI, n (%) | ||||
| Absent | 559 (67.8) | 545 (68.8) | 13 (40.6) | 0.003 |
| Present | 265 (32.2) | 247 (31.2) | 19 (59.4) | |
| Adjuvant chemotherapy, n (%) | ||||
| Absent | 709 (86.0) | 683 (86.2) | 26 (81.3) | 0.425 |
| Present | 115 (14.0) | 109 (13.7) | 6 (18.7) |
UC, urothelial carcinoma; NR, not reported; CIS, carcinoma in situ; LVI, lymphovascular invasion.